Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $94.20.

Several research firms recently commented on PBH. DA Davidson raised their price objective on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, August 28th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th.

Get Our Latest Analysis on Prestige Consumer Healthcare

Prestige Consumer Healthcare stock opened at $77.44 on Thursday. Prestige Consumer Healthcare has a twelve month low of $56.61 and a twelve month high of $79.25. The firm has a 50 day moving average price of $72.31 and a 200-day moving average price of $69.71. The company has a market capitalization of $3.84 billion, a P/E ratio of 18.93, a P/E/G ratio of 2.08 and a beta of 0.47. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare's revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.06 EPS. As a group, equities analysts predict that Prestige Consumer Healthcare will post 4.43 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Opal Wealth Advisors LLC purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $26,000. Quest Partners LLC raised its position in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after buying an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock valued at $33,000 after buying an additional 208 shares in the last quarter. Gladius Capital Management LP purchased a new position in Prestige Consumer Healthcare in the 2nd quarter worth $35,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after purchasing an additional 433 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Prestige Consumer Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.

While Prestige Consumer Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.